Baker Bros. Advisors LP 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Unchanged |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Baker Bros. Advisors LP | 2,368,378 4.300% |
0 (Unchanged) |
Filing |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Baker Bros. Advisors LP | 2,368,378 5.100% |
2,368,378 (New Position) |
Filing |